标题: Bloomberg BusinessWeek, July 30, 2018 [打印本页] 作者: choi 时间: 8-6-2018 14:47 标题: Bloomberg BusinessWeek, July 30, 2018 This is a "special issue" dedicated to "The New Space Age" -- as it is said in the cover.
Note:
(a)
(i) summary underneath the title in print: Blue Origin, the other space-obsessed billionaire's rocket company, isn't that far behind SpaceX
(ii) summary in table of contents: How's that other billionaire rocket maker doing?
(iii) Print and the online version are identical.
(b) "With a fortune of about $150 billion, according to the Bloomberg Billionaires Index, he's -Jeff Bezos's] the wealthiest person in the world. By a lot. He's worth approximately one Bill Gates and two and a half Elon Musks. One of his other companies, Amazon.com Inc, is now the world's second-most valuable corporation [after Apple] * * * He founded the rocket company 18 years ago in an old warehouse south of Seattle, originally stocking it with tinkerers and science fiction authors who could help reimagine space travel. Now the company, known in the space business as Blue, employs more than 1,500 software engineers and rocket scientists, most of them at its headquarters in Kent, Wash., and the West Texas launch site. It plans to launch New Shepard with test pilots on board as soon as this year, and in 2019 it will sell tickets to brave tourists who want to sit atop a tank of combustible liquid hydrogen and oxygen to experience four minutes of sublime weightlessness in suborbital space. The ticket price has yet to be revealed. But unlike other space startups that have to make the numbers work [SpaceX is private -- not selling stocks], Bezos largely funds the company himself by selling $1 billion in Amazon stock every year.
Seattle is the seat of King County (named after a person surnamed King), which includes City of Kent.
(c) "Blue Origin's eventual goal is 'millions of people living and working in space,' Bezos has said. He plans to get there 'step by step, ferociously,' according to Blue Origin's motto ('gradatim ferociter'), which adorns its coat of arms. * * * The rocket is tall, thick, and cone-tipped—its shape strenuously suggests off-color metaphors that shall not be deployed here [condom]. * * * space pioneers like the vessel's [New Shepard's] namesake, Alan Shepard * * * their [Bezos's and Musk's] styles and visions dramatically diverge. Bezos has said relatively little about Blue Origin outside the occasional speech and company promotional video. * * * SpaceX defenders will point out that Blue Origin's rockets have yet to reach orbit, a milestone SpaceX passed a full decade ago. And Musk has his eyes on distant planets in a way that Bezos doesn't."
(i) Latin-English dictionary:
* gradatim (adv; from [noun masculine] gradus step + [suffix] -ātim): "step by step, gradually" (compare Latin, and English, adverb verbatim: "word for word") https://en.wiktionary.org/wiki/gradatim
* ferociter (adv): "fiercely, ferociously, savagely" https://en.wiktionary.org/wiki/ferociter
The Latin root of English adjectives fierce and ferocious are ferus and ferox, respectively.
(d) "As a child, he devoured sci-fi books at the local library outside his grandfather's ranch in South Texas and eventually discovered the writings of Gerard K O'Neill, who spun visions of people living and working in space habitats."
(i) Jeff Bezos https://en.wikipedia.org/wiki/Jeff_Bezos
(section 1 Early life and education)
(ii) South Texas https://en.wikipedia.org/wiki/South_Texas
(South Texas is a region of the US state of Texas that lies roughly south of -- and sometimes including -- San Antonio)
(iii) Gerard K O'Neill https://en.wikipedia.org/wiki/Gerard_K._O%27Neill
(PhD in physics in 1954 from Cornell) 作者: choi 时间: 8-6-2018 14:48
(2) Cynthia Koons and Jared S Hopkins, A Cancer Cure Could Start in the Thermosphere. https://www.bloomberg.com/news/f ... tart-in-outer-space
Note:
(a)
(i) summary underneath the title in print: The advantages of pharmaceutical research on the International Space Station
(ii) Print and the online version are identical.
(b) "Shou-Ching Jaminet, a molecular biologist and former researcher at Harvard Medical School, spent almost a year preparing an experiment for her small biotech startup, Angiex [based in Cambridge, Massachusetts], to study the effects of weightlessness on a potential cancer drug. By June she was nervous with anticipation, readying her project for launch on an International Space Station resupply mission powered by a SpaceX Falcon 9 [which was launched at 5:42 am, June 29, 2018]. * * * The company, which Jaminet co-founded with her husband and a former Harvard colleague, would soon be among the more than 2,400 research projects started on the ISS since it went into service in 1998. * * * (Resupply missions also ferry food; Angiex's flight included maple[wood]-smoked salmon at one astronaut's request.) Jaminet's drug is intended to cut off the blood supply to tumors, thereby killing them. In space, she wants to observe how endothelial cells, which provide this blood, behave in microgravity. When a person has cancer, these cells can proliferate, promoting tumor growth. But it's not possible to run tests on them in a nonproliferating state on Earth. Jaminet's hypothesis is that they won't grow in culture aboard the ISS, making them similar to the cells in a healthy person’s blood vessels. Then, if the drug doesn’t harm these dormant endothelial cells, she’ll have evidence that it won’t damage patients' blood vessels on Earth, either, adding to the likelihood that the treatment will be safe."
(i)
(A) Shou-Ching Jaminet, PhD. Director of Multi-Gene Transcriptional Profiling, Center for Vascular Biology Research (CVBR), Beth Israel Deaconess Medical Center; Instructor of Pathology, Harvard Medical School.
cvbr.hms.harvard.edu/researchers/shih.html
("Shou-Ching S Jaminet earned her PhD in Cancer Immunology from Newcastle University, Newcastle, Australia in 1994. After post-doctoral research at Sloan Kettering Cancer Center, she became an Instructor at Boston Children's Hospital, in 2000. She joined BIDMC in 2005, where she established and leads the Multi-Gene Transcriptional Profiling Laboratory")
The alma mater is unheard of. Her email and street addresses indicates her laboratory is in the hospital, one of may teaching hospitals affiliated with Harvard Medical School (HMS). Her rank at HMS indicates her academic heft is insubstancial.
(B) "Shou-Ching was born in Korea to Chinese parents, attended college at National Taiwan University in Taipei": from the Web
Her maiden name is unknown.
(C) Her husband is Paul Jaminet, PhD is "a MIT- and Berkeley-trained astrophysicist” (from the Web; no longer doing astrophysics, though), and founder and CEO of Angiex.
(ii) She has money to burn. Since ancient time (whenever it is, when cancer became known), people knew cancer was supplied with nutrients in blood that came with new blood vessels (of course), and hope to figure out a way to stop formation of the new blood vessels. Nobody can (my hypothesis is of course not, because cancer cells are every bit like normal cells of the same person except for its uncontrolled growth. Incidentally, blood vessels large and small are lined with endothelial cells; capillaries are made up of "a single layer of flattened endothelial cells."
Capillaries. In The Histology Guide. University of Leeds, undated. https://www.histology.leeds.ac.uk/circulatory/capillaries.php
(iii) The lesson: Do not believe in hypes.